Widespread concern has been raised about political misinformation, which can result in greater polarization between the parties or less trust in government. In many cases, however, the subject of misinformation is medical care, including the safety of FDA-approved or cleared medical devices and drugs. The result of this deception can be much more serious – including risk to health and even loss of life.
By: Christopher White, Chief Operating Officer, General Counsel, Association Executive, AdvaMed
July 3, 2019
By: Scott Whitaker, President and CEO, AdvaMed
January 18, 2019
The Washington Post recently published an opinion piece by critic Jeanne Lenzer and a colleague which contained misleading and inaccurate claims regarding the safety of medical devices and FDA’s oversight of these products. I want to set the record straight so that patients can have confidence in the safety and effectiveness of the medical devices they depend on to live longer, healthier, more productive lives.
By: Scott Whitaker, President and CEO, AdvaMed
October 11, 2018
Last week, an article by Barbara Bridgman Perkins, PhD, was published in the Washington Post admonishing the relationships between industry and health care providers to advance radiotherapy treatment. Here is what I submitted in response.
By: Jeff Mirviss, President, Peripheral Interventions Division, Boston Scientific
July 23, 2018
When we talk about “life-changing medical innovation,” we’re really talking about patients like Susan and millions of Americans like her. And when we talk about the “medical device industry,” we’re talking about the thousands of people working at 600+ device manufacturers in Medical Alley alone whose work led to breakthroughs like the procedure that changed Susan’s life. These people are working today on the breakthroughs that will help patients tomorrow.
By: Christopher White, Chief Operating Officer, General Counsel, Association Executive, AdvaMed
June 8, 2018
For the past several years, policymakers and industry have been exploring ways to improve the quality of health care furnished to individuals while promoting efficiency and value. As I have discussed in the past, I believe that medical technology companies can be a key player in these coordinated care efforts in light of their specialized clinical knowledge, economic expertise, data analytics proficiency, and supply chain management capability. Unfortunately, various regulatory roadblocks stand in the way of the medtech industry’s full participation in the shift to more coordinated care.